Second GMP Galidesivir campaign commissioned to build outbreak and biodefence inventory
Island Pharmaceuticals (ASX: ILA) has commissioned a second GMP-grade Galidesivir manufacturing campaign with global contract research, development and manufacturing organisation PI Health Sciences (PIHS). The additional production is intended to materially expand the Company’s available drug supply for active outbreak response and broader biodefence opportunities.
Combined with previously commissioned supply, Island expects to have approximately 700–800 treatment courses of Galidesivir available in Q4 CY26.
The decision represents a strategic shift for the program. Rather than manufacturing solely to meet the requirements of individual studies, the Company is building a deployable inventory position capable of responding rapidly to outbreak, biodefence and government opportunities as they arise.
The timing is anchored to a serious backdrop: the ongoing Bundibugyo Ebola outbreak continues to spread rapidly across Central Africa, including The Democratic Republic of Congo and Uganda.
When big ASX news breaks, our subscribers know first
The numbers behind the inventory build
The following table summarises the key manufacturing and supply details underpinning Island’s expanded inventory position.
| Metric | Detail |
|---|---|
| Manufacturer | PI Health Sciences (PIHS) |
| Expected completion | Q4 CY26 |
| Total treatment courses available | ~700–800 |
| Prior engagement reference | Initial PIHS campaign (4 June 2026) |
| Deployment pathway | MEURI in Uganda (approved 7 July 2026) |
The strategic logic is straightforward: inventory equals capability. Governments and biodefence agencies tend to engage more seriously when a company already holds deployable drug, as inventory signals readiness rather than intention.
A rapidly escalating outbreak raises the stakes
The urgency behind the timing is driven by the severity of the current outbreak. As at 18 August 2026, the Bundibugyo Ebola epidemic had recorded:
- 5,208 confirmed cases
- 2,476 deaths
- A 47.5% case-fatality rate, making it one of the most significant Ebola epidemics on record
- Spreading five times faster than previous outbreaks at the same stage
- A Bundibugyo strain with no approved therapeutic treatment or vaccine
According to the Company, the Bundibugyo strain is highly transmissible, often misdiagnosed early and carries “walking Ebola” characteristics. This means infected individuals can move through communities before detection, which makes early treatment rarely possible and underscores the importance of delayed-dosing efficacy in any candidate therapeutic.
Understanding Galidesivir: what it is and why it matters
Galidesivir is a clinical-stage, broad-spectrum antiviral molecule with demonstrated activity across more than 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow Fever.
Its relevance to the current outbreak flows from two regulatory pathways. The first is MEURI, the World Health Organization (WHO) recognised Monitored Emergency Use of Unregistered and Investigational Interventions framework. MEURI allows investigational drugs to be used during outbreaks when no approved treatment exists, enabling the generation of real human data.
The second is the FDA Animal Rule, a specialised regulatory pathway that allows approval based on controlled non-human primate (NHP) efficacy when human trials are not feasible.
The FDA Animal Rule pathway removes the requirement for human efficacy trials by substituting controlled non-human primate data, provided the animal model reliably predicts human response, a threshold Island secured formal FDA alignment on earlier this year.
For investors, the two pathways are complementary. Island expects Galidesivir to be deployed in Uganda under MEURI during CY26, providing the opportunity to generate prospective human efficacy, safety and virological data. This directly complements the Company’s existing pathway for potential approval for use in Marburg under the FDA’s Animal Rule.
The efficacy data underpinning the program
The primate data gives the inventory much of its strategic value. Key efficacy points reported by the Company include:
- 100% survival in the Ebola Zaire (Kikwit) NHP model when treatment began 48 hours post-infection.
- 67% survival even when dosing was delayed to 72 hours or administered without a loading dose.
- 94% survival in the Marburg NHP model with treatment starting 48 hours post-infection.
- In all studies, every untreated control animal died.
The significance for real-world deployment lies in the delayed-dosing windows. Because outbreaks rarely allow immediate treatment, efficacy demonstrated with delayed dosing is important for practical use. The multi-filovirus activity also strengthens the Animal Rule package and supports potential procurement across multiple filovirus threats.
Management commentary
Dr David Foster, CEO and Managing Director
“Before the end of CY26, we expect to have around 700–800 treatment courses available. This represents a considerable strategic inventory and importantly gives us the ability to pursue opportunities without having to commence a new manufacturing campaign each time a potential requirement emerges.”
“Our strategy, however, extends beyond any single outbreak. We are building Galidesivir as a broad-spectrum medical and biodefence countermeasure while concurrently undertaking the required initiatives for broader approval and believe maintaining a meaningful inventory of GMP-grade drug materially strengthens our ability to engage with governments, biodefence agencies and other potential partners around outbreak preparedness, procurement and stockpiling.”
The investment thesis: from inventory to commercial pathways
The inventory build connects to a broader commercial and biodefence opportunity. The Company points to several supporting factors:
- Animal Rule countermeasures have generated between US$100m and US$1.2bn in lifetime sales since 2012, averaging US$625m.
- A Marburg countermeasure remains the only Category A biothreat with no antiviral in the U.S. Strategic National Stockpile (SNS).
- The U.S. government has spent approximately US$600m in grants to date pursuing a Marburg antiviral, with no successful product.
- A Priority Review Voucher (PRV) has historically been worth around US$200m on the secondary market.
- Every successful Animal Rule countermeasure that has received FDA approval has been procured into the SNS.
For investors exploring the depth of Island’s biodefence execution capability, our detailed coverage of the Raymond Taylor appointment profiles a former BioCryst executive who led the original Galidesivir development program and secured more than US$490 million in US Government funding, including over US$125 million in SNS procurement contracts.
Taken together, the Company believes a meaningful inventory position Island for procurement, stockpiling and government engagement, rather than supplying only individual studies.
What’s next: timelines and strategic roadmap
The forward pathway centres on several key milestones:
- Manufacturing completion: Q4 CY26
- MEURI deployment in Uganda: during CY26
- NDA preparation: begins Q3 CY27, following pivotal Marburg Angola studies
The dual regulatory approach remains central to the thesis. The Animal Rule provides controlled efficacy data, while MEURI is expected to provide real-world human data. Together, the Company believes they create a uniquely strong regulatory package.
Island’s stated long-term strategy is to accelerate Galidesivir into a revenue generator for shareholders as a broad-spectrum antiviral and biodefence countermeasure, supported by Animal Rule approval, MEURI human data and a substantial GMP inventory capable of rapid deployment.
Don’t Miss the Next Biotech Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare and biotech alerts directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of the market. Click the “Free Alerts” button at Big News Blast to get the next market-moving announcement the moment it drops.